Overview

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Status:
ENROLLING_BY_INVITATION

Trial end date:
2029-08-01

Target enrollment:

Participant gender:

Summary

After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the efficacy of trastuzumab deruxtecan in terms of progression-free survival (PFS).

Phase:

PHASE2

Details

Lead Sponsor:

UNICANCER

Collaborators:

AstraZeneca
Breast Cancer Research Foundation